NOVEL
Beyond's analysis on NOVEL
Recent news mentioning NOVEL
- — THE SAINT YOU THOUGHT YOU KNEW: CHARLES GAINES' FINAL NOVEL REIMAGINES ST. FRANCIS AS A MAN OF SEX, LOVE, POWER, DOUBT AND FAITH
- — GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)
- — Two Independent Research Teams Converge on Novel Immune Checkpoint PLA2G2D as a Path to Overcome Anti-PD-1 Resistance in Cancer
- — Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
- — InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China
- — Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
- — Altesa BioSciences Presents Novel Clinical Data Demonstrating Vapendavir Significantly Reduces Key Inflammatory Biomarkers in Rhinovirus-Challenged COPD Patients at the European Respiratory Society International Congress 2026
- — The Novel Imagining Life After a Second Civil War
- — Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
- — SEC’s ‘Novel ETF’ Review Puts Prediction Market And Leveraged Funds Under Microscope
- — Crypto Groups Push SEC for Tailored Rules on Novel ETFs
- — Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
Appears alongside
Browse the full archive →